Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Icecure Medical ( (ICCM) ) just unveiled an announcement.
On May 12, 2026, IceCure Medical reported first-quarter 2026 results showing a 26% rise in global revenue to $911,000, driven by strong demand for its ProSense® cryoablation system in North America, where sales rose 84% and U.S. sales grew 31%. Gross profit climbed 35% and gross margin improved to 32%, but higher research and development and general and administrative costs widened the quarterly net loss to $4.3 million, while cash and equivalents slipped to $8.1 million as of March 31, 2026.
The company highlighted a 46% increase in active U.S. ProSense® customer accounts following FDA clearance for low-risk breast cancer at the end of 2025, expanding from 13 to 19 accounts, and immediate adoption by new hospitals in Alabama and Missouri. IceCure is accelerating its U.S. commercial push with an eight-region sales footprint, the FDA-approved 30-site ChoICE post-marketing study, and growing clinical validation including updated guidelines recommending cryoablation, cost data showing 50% savings versus lumpectomy, and positive five-year kidney cancer results, all of which strengthen its positioning in minimally invasive oncology.
The most recent analyst rating on (ICCM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
ICCM scores low overall primarily due to weak financial performance (large losses and significant cash burn despite modest revenue) and bearish technicals (below major moving averages with negative MACD). The latest earnings call adds meaningful upside from regulatory validation and stated commercial acceleration plans, but near-term execution and reimbursement timing risks keep the overall score constrained.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is a medical device company that develops and markets advanced liquid-nitrogen-based cryoablation systems for destroying benign and malignant tumors by freezing. Its flagship minimally invasive ProSense® platform targets breast, kidney, bone and lung cancers and is marketed globally, including in the U.S., Europe and Asia, as an alternative to surgical tumor removal.
Average Trading Volume: 556,184
Technical Sentiment Signal: Sell
Current Market Cap: $16.49M
See more insights into ICCM stock on TipRanks’ Stock Analysis page.